TD Cowen initiated coverage of Septerna (SEPN) with a Buy rating and no price target The company is applying its Native Complex platform to build a pipeline of oral small molecule G protein-coupled receptor drugs, the analyst tells investors in a research note. The firm sees “significant potential for stock appreciation” based on Septerna’s validated targets in sizable markets.
Don't Miss out on Research Tools:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SEPN:
- Septerna initiated with an Overweight at JPMorgan
- Opening Day: Invizyne Technologies jumps after IPO
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
